{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:10:01Z","timestamp":1790763001810,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,6,9]],"date-time":"2008-06-09T00:00:00Z","timestamp":1212969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The present study evaluated the expression of hepcidin mRNA in hepatocellular carcinoma (HCC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Samples of cancerous and non-cancerous liver tissue were taken from 40 patients with HCC who underwent hepatectomy. Expression of hepcidin mRNA was evaluated by real-time PCR, and compared in tumors differing in their degree of differentiation, number of tumors, and vessel invasion. Correlations between hepcidin expression and the interval until HCC recurrence, and the serum concentration of hepcidin were evaluated, together with the expression of mRNAs for other iron metabolism molecules, ferroportin and transferrin receptor 2 (Trf2).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Hepcidin mRNA expression in non-cancerous and cancerous tissues was 1891.8 (32.3\u201323187.4) and 53.4 (1.9\u20133185.8), respectively (<jats:italic>P<\/jats:italic> &lt; 0.0001). There were no significant differences in hepcidin expression among tumors differing in their degree of differentiation, number of tumors, or vessel invasion. There was no significant correlation between hepcidin expression and the interval until HCC recurrence. The serum concentration of hepcidin-25 was not correlated with hepcidin-mRNA expression. Finally, there were no significant differences in the expression of mRNA for ferroportin and Trf2 between cancerous and non-cancerous tissues.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Expression of hepcidin mRNA is strikingly suppressed in cancerous, but not in non-cancerous tissues, in patients with HCC, irrespective of ferroportin or Trf2 expression. Uniform suppression of hepcidin may be linked to the development of HCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-8-167","type":"journal-article","created":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T06:14:08Z","timestamp":1213078448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma"],"prefix":"10.1186","volume":"8","author":[{"given":"Hiroaki","family":"Kijima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokihiko","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Tomosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,9]]},"reference":[{"key":"1105_CR1","volume-title":"GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0","author":"J Ferlay","year":"2001","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. 2001, Lyon: IARC Press"},{"issue":"5 Suppl 1","key":"1105_CR2","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127 (5 Suppl 1): S35-S50. 10.1053\/j.gastro.2004.09.014.","journal-title":"Gastroenterology"},{"key":"1105_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0168-8278(98)80371-1","volume":"28","author":"Y Deugnier","year":"1998","unstructured":"Deugnier Y, Turlin B, Lor\u00e9al O: Iron and neoplasia. J Hepatol. 1998, 28: 21-25. 10.1016\/S0168-8278(98)80371-1.","journal-title":"J Hepatol"},{"key":"1105_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","volume":"117","author":"MW Hentze","year":"2004","unstructured":"Hentze MW, Muckenthaler MU, Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004, 117: 285-297. 10.1016\/S0092-8674(04)00343-5.","journal-title":"Cell"},{"key":"1105_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/0016-5085(92)90339-Z","volume":"102","author":"AM Di Bisceglie","year":"1992","unstructured":"Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR: Measurement of iron status in patients with chronic hepatitis. Gastroenterology. 1992, 102: 2108-213.","journal-title":"Gastroenterology"},{"key":"1105_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1572-0241.2004.04049.x","volume":"99","author":"MA Metwally","year":"2004","unstructured":"Metwally MA, Zein CO, Zein NN: Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol. 2004, 99: 286-291. 10.1111\/j.1572-0241.2004.04049.x.","journal-title":"Am J Gastroenterol"},{"key":"1105_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1440-1746.2006.04548.x","volume":"22","author":"M Yamamoto","year":"2007","unstructured":"Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, Mifuji R, Konishi M, Kobayashi Y, Adachi Y: Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007, 22: 498-503. 10.1111\/j.1440-1746.2006.04548.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"1105_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/bcmd.2002.0573","volume":"29","author":"G Nicoras","year":"2002","unstructured":"Nicoras G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S: Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002, 29: 327-335. 10.1006\/bcmd.2002.0573.","journal-title":"Blood Cells Mol Dis"},{"key":"1105_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","volume":"102","author":"T Ganz","year":"2003","unstructured":"Ganz T: Hepcidin: a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003, 102: 783-788. 10.1182\/blood-2003-03-0672.","journal-title":"Blood"},{"key":"1105_CR10","doi-asserted-by":"publisher","first-page":"G199","DOI":"10.1152\/ajpgi.00412.2005","volume":"290","author":"T Ganz","year":"2006","unstructured":"Ganz T, Nemeth E: Iron Imports IV: Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointestinal Liver Physiol. 2006, 290: G199-G203. 10.1152\/ajpgi.00412.2005.","journal-title":"Am J Physiol Gastrointestinal Liver Physiol"},{"key":"1105_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/ncpgasthep0019","volume":"1","author":"A Pietrangelo","year":"2004","unstructured":"Pietrangelo A, Trautwein C: Mechanism of disease: the role of hepcidin in iron homeostasis \u2013 implications for hemochromatosis and other disorders. Nat Clin Prac Gastroenterol Hepatol. 2004, 1: 39-45. 10.1038\/ncpgasthep0019.","journal-title":"Nat Clin Prac Gastroenterol Hepatol"},{"key":"1105_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1136\/gut.2003.037416","volume":"53","author":"DM Frazer","year":"2004","unstructured":"Frazer DM, Inglis HR, Wilkins SJ, Millard KN, Steele TM, McLaren GD, McKie AT, Vulpe CD, Anderson GJ: Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis. Gut. 2004, 53: 1509-1515. 10.1136\/gut.2003.037416.","journal-title":"Gut"},{"key":"1105_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI0215686","volume":"110","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002, 110: 1037-1044.","journal-title":"J Clin Invest"},{"key":"1105_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jso.20388","volume":"92","author":"Y Iso","year":"2005","unstructured":"Iso Y, Sawada T, Okada T, Kubota K: Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol. 2005, 92: 304-311. 10.1002\/jso.20388.","journal-title":"J Surg Oncol"},{"key":"1105_CR15","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1182\/blood-2005-10-4043","volume":"108","author":"N Tomosugi","year":"2006","unstructured":"Tomosugi N, Kawabata H, Watanabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I: Detection of serum hepcidin in renal failure and inflammation by using proteinchip system. Blood. 2006, 108: 1381-1387. 10.1182\/blood-2005-10-4043.","journal-title":"Blood"},{"key":"1105_CR16","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2003-03-0953","volume":"103","author":"AII Laftah","year":"2004","unstructured":"Laftah AII, Ramesh B, Simpson R, Solanky N, Bahram S, Sch\u00fcmann K, Debnam ES, Srai SK: Effect of hepcidin on intestinal iron absorption in mice. Blood. 2004, 103: 3940-3944. 10.1182\/blood-2003-03-0953.","journal-title":"Blood"},{"key":"1105_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1073\/pnas.0409409102","volume":"102","author":"MD Kuston","year":"2005","unstructured":"Kuston MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M: Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA. 2005, 102: 1324-1328. 10.1073\/pnas.0409409102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1105_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/hep.1840150417","volume":"15","author":"S Fargion","year":"1992","unstructured":"Fargion S, Mandelli C, Piperno A, Cecana B, Fracanzani AL, Fraquelli M, Bianchi PA, Fiorelli G, Conte D: Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992, 15: 655-659. 10.1002\/hep.1840150417.","journal-title":"Hepatology"},{"key":"1105_CR19","first-page":"31","volume":"1603","author":"NT Le","year":"2002","unstructured":"Le NT, Richardson DR: The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002, 1603: 31-46.","journal-title":"Biochim Biophys Acta"},{"key":"1105_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2141.2007.06638.x","volume":"138","author":"O Weizer-Stern","year":"2007","unstructured":"Weizer-Stern O, Adamsky K, Margalit O, Ashur-Febian O, Givol D, Amariglio N, Rechavi G: Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol. 2007, 138: 253-262. 10.1111\/j.1365-2141.2007.06638.x.","journal-title":"Br J Haematol"},{"key":"1105_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/351453a0","volume":"351","author":"AJ Levine","year":"1991","unstructured":"Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature. 1991, 351: 453-456. 10.1038\/351453a0.","journal-title":"Nature"},{"key":"1105_CR22","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1038\/sj.onc.1209547","volume":"25","author":"P Laurent-Puig","year":"2006","unstructured":"Laurent-Puig P, Zuckman-Rossi J: Genetics of hepatocellular tumors. Oncogene. 2006, 25: 3778-3786. 10.1038\/sj.onc.1209547.","journal-title":"Oncogene"},{"key":"1105_CR23","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1152\/ajpgi.00415.2005","volume":"290","author":"M Wessling-Resnic","year":"2006","unstructured":"Wessling-Resnic M: Iron imports III: Transfer of iron from mucosa into circulation. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G1-G6. 10.1152\/ajpgi.00415.2005.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1105_CR24","doi-asserted-by":"publisher","first-page":"G199","DOI":"10.1152\/ajpgi.00412.2005","volume":"290","author":"T Ganz","year":"2006","unstructured":"Ganz T, Nemeth E: Iron Imports IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointestinal Liver Physiol. 2006, 290: G199-G203. 10.1152\/ajpgi.00412.2005.","journal-title":"Am J Physiol Gastrointestinal Liver Physiol"},{"key":"1105_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2141.2004.05224.x","volume":"127","author":"H Kawabata","year":"2004","unstructured":"Kawabata H, Tong X, Kawanami T, Wano Y, Hirose Y, Sugai S, Koeffler HP: Analyses for binding of the transferrin family of proteins to the transferrin receptor 2. Br J Haematol. 2004, 127: 464-473. 10.1111\/j.1365-2141.2004.05224.x.","journal-title":"Br J Haematol"},{"key":"1105_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1136\/gut.2004.062018","volume":"54","author":"DF Wallace","year":"2005","unstructured":"Wallace DF, Summerville L, Lusby PE, Subramanian VN: First phenotypic description of transferrin receptor 2 knockout mouse, and role of hepcidin. Gut. 2005, 54: 980-986. 10.1136\/gut.2004.062018.","journal-title":"Gut"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-167\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:33:37Z","timestamp":1630463617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-8-167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-167","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,9]]},"assertion":[{"value":"13 February 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"167"}}